Thonsgaard, 2022

5

All information in a reference can be edited from Study Inspector or within each module.

1. Navigate to the Abstract of interest

If you are already on the reference of interest, simply go to the Abstract tab.

If you are searching for the record you need to edit, the best way to search is from Inspector.

2. Click the Edit button

Abstract Full Text Supplements Related Reports

The button is found at the lower right of the reference information.

Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men. BACKGROUND C-type natriuretic peptide (CNP) is a cardioprotective peptide with high affinity for the ectoenzyme neutral endopeptidase (neprilysin). We aimed to determine whether angiotensin receptor-neprilysin inhibitor treatment acutely affects circulating concentrations of bioactive CNP and its molecular amino-terminal precursor (NT-proCNP). METHODS We included 9 and 10 healthy young men in 2 randomized crossover trials with <u>sacubitril</u>/valsartan vs control (Trial 1) and <u>sacubitril</u>/valsartan and sitagliptin vs sitagliptin (Trial 2). The participants were randomized to a single dose of <u>sacubitril</u>/valsartan (194/206 mg) or control at the first visit 30 min prior to a standardized meal intake. We obtained blood samples at 12 time points over 5 h and measured plasma concentrations of NT-proCNP in both trials and CNP in Trial 2. RESULTS NT-proCNP concentrations increased 3.5 h after <u>sacubitril</u>/valsartan treatment, and at 4.5 h concentrations were 42% and 65% higher compared with control in Trial 1 and Trial 2, respectively. The total area under the curve (tAUC)15-270 min was 22% higher (P = 0.007) in Trial 1 and 17% higher with treatment (P = 0.017) in Trial 2. Concentrations of bioactive CNP followed a similar temporal pattern with an increase of 93% at 4.5 h and a 31% higher tAUC15-270 min compared with control (P = 0.001) in Trial 2. CONCLUSIONS Sacubitril/valsartan augments circulating concentrations of both bioactive CNP and NT-proCNP in healthy young men. The increase in bioactive CNP is most likely caused by de novo synthesis and secretion rather than diminished breakdown through neprilysin inhibiton.ClinicalTrials.gov registration number NCT03717688.

Population/Problem Intervention Outcome) Your Keywords 🖉 —	
(Keywords	V Bibliographic fields	Edit

3. Add, remove, or modify the information.

In the modal that appears, any Bibliographic Data can be changed by typing in the relevant field.

Changing Author Order

Author order can be modified using the buttons to the right (red box in the image below).

- Authors can be reordered using the arrows to the side.
- Authors can be removed using the minus button next to the author's name.

PubMed

Last update: 2023/03/13 wiki:autolit:search:editreferences https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:search:editreferences&rev=1678738916 20:21

• Authors can be added below any existing author using the plus button next to the existing author's name.

Dual Abstract Screening: Dua	al Two Pass: HF				-Å-	13	/ 16)?
Nest Home	Abstract Full Text Supplements	Related Reports		同 543	⊙ 13 ⊘ 529 ③ 3 PubMed ∨	+	Navigation	~
Dashboard	Armstrong, 2020		Edit Metadata				-	(Skip)
Settings	Vericiguat in Patients with He							
Literature Search	BACKGROUND The effect of vericious)	and reduced ejection fraction who had	↔ A	bstract Screenin	ig 🔨
	recently been hospitalized or had rece	Conflict of Interest:			d, double-blind, placebo-controlled	Full Text Re	view 🗌 Train Incl	lusion Model
Other Sources Duplicate Review	trial, we assigned 5050 patients with)	fraction of less than 45% to receive			1
Search Exploration	vericiquat (target dose, 10 mg once da	Corporate Author: VICTORIA Study Group			me was a composite of death from	Exclude:		
	cardiovascular causes or first hospital	Grant Information:)	ne event occurred in 897 of 2526			
Abstract Screening 13/16	patients (35.5%) in the vericiquat gro	Grant Information:			% confidence interval [CI], 0.82 to		Select Reason 🗟	
Configure Screening Adjudicate Screening	0.98; P = 0.02). A total of 691 patients	Drug or Device Name:	Drug or Device Manu	ufacturer:	re hospitalized for heart failure			
	(hazard ratio, 0.90; 95% CI, 0.81 to 1.0				guat group and in 441 patients	Duplication		
Full Text Screening 4/5	(17.5%) in the placebo group (hazard r	First Name:	Last Name:	Merge	lization for heart failure occurred in	new ex		
Adjudicate Screening	957 patients (37.9%) in the vericiguat	Paul W	Armstrong	\bigtriangledown	CI, 0.83 to 0.98; P = 0.02).	Does not r	eport therapies of intere	st
	Symptomatic hypotension occurred in	First Name:	Last Name:	Merge	cebo group (P = 0.12), and <mark>syncope</mark>	Does not r	eport patient outcomes	
Tagging 0/4	occurred in 4.0% of the patients in th	Burkert	Pieske	$\bigcirc \bigcirc $	ICLUSIONS Among patients with	Published	Before 2010-01-01	
Configure Tagging	high-risk heart failure, the incidence o	First Name:	Last Name:	Merge	mong those who received vericiguat	Not Publis	hed in English	
Extraction 1/4	than among those who received place	Kevin J	Anstrom		IA ClinicalTrials.gov number,	Advance:		
	NCT02861534.).	First Name:	Last Name:	Merge			Advance	
Configure Extraction		Justin	Ezekowitz			-		
Study Inspector	Population/Problem Intervent	First Name:	Last Name:	Merge		+	Tagging	\sim
	(Keywords	Adrian F) (Hernandez		→ (Edit)	(+)	Comments (6)	\sim
Synthesis	Reywords	First Name:	Last Name:	Merge		-	comments (o)	
Manuscript Editor		Javed) (Butler			(+)	History	\sim
Abstract Editor Export		First Name:	Last Name:	Merge				
Export		Carolyn S P First Name:	Lam					
		Piotr	Ponikowski					
		First Name:	Last Name:	Merge				
		Advison A	Voor					
		Cancel	Sync ?	Save				

The save button is found at the bottom of the Edit Metadata window (blue box in the image above).

When completed, you can open the Bibliographic Fields drop-down to review and confirm that the bibliographic data is correct and complete!

Sync Updated Bibliographic Data

If for any reason, the bibliographic data of a specific record needs updating, you can click the "Sync" button for any individual record during screening.

This action updates the data based on the information available on PubMed or CrossRef and overwrites the existing data if they do not match.

Edit References

Dual Abstract Screening: Dual	al Two Pass: HF				-ŷ-	13	3/16	?
Nest Home	Abstract Full Text Supplements	Related Reports		圖 543	⊙ 13 ⊘ 529 ⊙ 3 PubMed ∨	+	Navigation	^
Dashboard Settings	Armstrong, 2020		Edit Metadata					Skip
Utterature Search Other Sources Duplicate Review Search Exploration	Vericiguat in Patients with He BACKGROUND The effect of vericigu recently been hospitalized or had rece trial, we assigned 5050 patients with vericiguat (target dose, 10 mg once di	Conflict of Interest:			ind reduced ejection fraction who had d, double-blind, placebo-controlled i fraction of less than 45% to receive me was a composite of death from	++ / Full Text Re Upload		lusion Model
Abstract Screening 13/16 Configure Screening Adjudicate Screening	cardiovascular causes or first hospital patients (35.5%) in the vericiguat gro 0.98; P = 0.02). A total of 691 patients	Control Study Group Grant Information: Grant Information: Drug or Device Name: Drug or Device Manufacturer: Drug or Device Manufacturer: Drug or Device Name: Drug or Device Manufacturer:						
Full Text Screening 4/5 Adjudicate Screening	(hazard ratio, 0.90; 95% CI, 0.81 to 1.0 (17.5%) in the placebo group (hazard r 957 patients (37.9%) in the vericiguat	First Name: Paul W	Last Name: Armstrong		guat group and in 441 patients dization for heart failure occurred in Cl, 0.83 to 0.98; P = 0.02).	Duplication new ex Does not r	n report therapies of intere	st
Tagging 0/4	Symptomatic hypotension occurred ir occurred in 4.0% of the patients in th high-risk heart failure, the incidence of	First Name: Burkert First Name:	Last Name: Pieske Last Name:	Merge	cebo group (P = 0.12), and syncope VCLUSIONS Among patients with mong those who received vericiguat	Published	report patient outcomes Before 2010-01-01 shed in English	
Extraction 1/4	than among those who received place NCT02861534.).	Kevin J First Name:	Anstrom Last Name: Ezekowitz		IA ClinicalTrials.gov number,	Advance:	Advance	
Study Inspector	Population/Problem Intervent	First Name: Adrian F	Last Name: Hernandez	Merge		↔ 	Tagging	~
Synthesis Manuscript Editor Abstract Editor Export	(Keywords	First Name: Javed First Name: Carolyn S P	Last Name: Butler Last Name: Lam	Merge Merge (V A) (-+)	Edit	↔	Comments (6) History	~
		First Name: Piotr First Name: Advisors A	Last Name: Ponikowski Last Name: Veore	Merge				
		Cancel	Sync ?	Save				

From:

https://wiki.nested-knowledge.com/ - Nested Knowledge

Permanent link:

https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:search:editreferences&rev=1678738916

Last update: 2023/03/13 20:21